Abstract. The HMG-CoA reductase inhibitors (statins) have been shown to exert several vascular protective effects that are not related to changes in cholesterol profile, and these effects of statins are partly caused by the activation of angiogenesis. Endothelial cell (EC) proliferation and migration are crucial events for angiogenesis and statins are known to enhance these events. However, the molecular mechanism by which statins promote EC proliferation and migration is not fully understood. In this study, we show Akt and its downstream target mammalian target of rapamycin (mTOR) play an important role in pravastatin-induced EC proliferation and migration. We found that pravastatin significantly enhanced the proliferation and migration of rat aortic endothelial cells (rAECs). The addition of pravastatin to rAECs resulted in rapid phosphorylation of Akt and p70 S6 kinase (p70S6K). LY294002, a specific inhibitor of phosphatidylinositol 3-kinase (PI3K), blocked both Akt and p70S6K phosphorylation, whereas rapamycin, a specific inhibitor of mTOR, suppressed only p70S6K phosphorylation induced by pravastatin. Furthermore, both LY294002 and rapamycin inhibited pravastatin-induced rAEC proliferation and migration. Taken together, our findings indicate that pravastatin activates PI3K / Akt/ mTOR / p70S6K signaling in this sequential manner and this pathway contributes to pravastatin-induced rAEC proliferation and migration.
Introduction
The HMG-CoA reductase inhibitors, known as statins, are generally used as therapeutic agents for the treatment of hypercholesterolemia (1) . However, recent in vivo and in vitro studies have demonstrated that the drugs have additional vasculoprotective effects independent of cholesterol lowering: statins improve endothelial function, reduce vascular inflammation, decrease platelet aggregation, and enhance endothelial processes involved in angiogenesis (2 -6) . Angiogenesis is a complex multistep process by which blood vessels are formed from the preexisting vasculature. All forms of angiogenesis are thought to share certain basic features, including degradation of the parent venule basement membrane, endothelial cell (EC) proliferation and migration, development of sprouts, and generation of new basement membrane (7) . Recent studies have shown that statins promote angiogenic processes, including EC proliferation and migration (8 -10) . However, the mechanisms underlying these serum lipidindependent effects of statins are not completely understood.
It is well established that activation of phosphatidylinositol 3-kinase (PI3K) plays an important role in promoting cell survival and proliferation in numerous cell systems (11) . PI3K has been shown to be activated by many proangiogenic factors, including vascular endothelial growth factor (VEGF) (12) and basic fibroblast growth factor (bFGF) (13) . Activation of PI3K results in recruitment of the serine-threonine kinase Akt, one of the downstream targets of PI3K, to the plasma membrane, where it is activated by the 3-phosphoinositide-dependent kinase PDK1. Activated Akt affects the activity or abundance of a number of transcription factors linked to cell survival and proliferation (11) . In ECs, it has been shown that the majority of growth factor-induced responses are mediated by the activation of the PI3K / Akt signaling cascade (14) . It has also been shown that statins rapidly induce the activation of Akt in these cells (6) .
In this study, we directed our attention to the molecular mechanisms by which statins induce proliferation and migration in ECs. We found that EC proliferation and migration were enhanced by pravastatin, and this effect was mediated by PI3K/ Akt-induced mammalian target of rapamycin (mTOR)/ p70 S6 kinase (p70S6K) activation in rat aortic ECs.
Materials and Methods

Reagents and antibodies
Pravastatin was kindly provided by Sankyo Co., Ltd. (Tokyo). LY294002 and rapamycin were purchased from Calbiochem (San Diego, CA, USA). Mevalonate was purchased from Sigma (St. Louis, MO, USA). Antibodies against phospho-Akt, total-Akt, phosphop70S6K, total-p70S6K, phospho-FOXO1 / O3a, phosphor-FOXO3a (Ser 253), and total-FOXO1 were purchased from Cell Signaling Technology Inc. (Beverly, MA, USA). An antibody for native FOXO3a was purchased from Upstate Biotechnology (Lake Placid, NY, USA) and the monoclonal anti-α-tubulin antibody was purchased from Oncogene (Boston, MA, USA). Secondary antibodies used were horseradish peroxidase (HRP)-conjugated anti-rabbit immunoglobulin G (IgG) and HRP-conjugated anti-mouse IgG from Bio-Rad Laboratories (Hercules, CA, USA).
Culture of rat aortic endothelial cells (rAECs)
rAECs were isolated from adult Sprague-Dawley rats (Clea Japan, Tokyo) by the explant technique (15) . The cells were cultured in DMEM supplemented with 10% FBS, 1% penicillin-streptomycin, and 0.15 mg / ml EC growth supplement (Cambrex, Walkersville, MD, USA) at 37°C in a 95% air / 5% CO 2 incubator. Throughout the rAEC cultures, 0.1% gelatin-coated 60-mm culture dishes were used. Experiments were performed on cells at passage 3 from primary culture. rAECs were identified by DiI-Ac-LDL uptake experiments. All procedures were in accordance with institutional guidelines for animal research.
Cell proliferation assay rAECs (3 × 10 4 ) were seeded onto 6-well plates and incubated in serum-reduced media (DMEM containing 1% FBS and 0.015 mg / ml EC growth supplement) for 18 h. Cells were then treated with pravastatin in the presence or absence of LY294002 or rapamycin for an additional 72 h. Viable cell numbers were monitored by trypan blue dye exclusion.
Scratch wound assay
rAECs were seeded onto gelatin-coated 6-cm dishes and allowed to form confluent monolayers. The cell monolayer was scraped with a 1-ml pipette tip to create a cell-free zone. Thereafter, cells were washed with medium and cultured either without or with pravastatin (1 µM) in the absence or presence of the inhibitors. After 48 h of incubation, photographs were taken with a Nikon Eclipse TE300 (Nikon, Tokyo).
Boyden chamber assay
The chemotaxis assay was performed in a 48-well Boyden chemotaxis chamber (Neuro Probe, Gaithersburg, MD, USA) as previously described (16) . Briefly, rAECs were preincubated with pravastatin (1 µM) for 24 h and cells were trypsinized and washed twice with phosphate-buffered saline (PBS); and then aliquots (50 µl) of rAECs suspension (1 × 10 6 cells / ml) were added to the upper well of the chamber, which was separated from the lower well by a 8-µm-pore-size, polycarbonate membrane (Neuro Probe). The bottom wells of the chemotaxis chamber were filled with 0.25% BSA/ DMEM containing 10 ng / ml VEGF. The chamber was incubated for 4 h at 37°C in an atmosphere containing 5% carbon dioxide. The membrane was then carefully removed and all non-migrant cells were removed from the upper surface of the membrane with a rubber swab. rAECs that migrated to the lower surface of the membrane were fixed and stained with Diff-Quick (International Reagents Corp., Hyogo). The number of cells migrated to the lower surface of the filter was evaluated microscopically by counting the number of stained nuclei per high-power field (×400). All assays were performed in triplicate, and each sample was counted randomly in four different areas in the center of the membrane.
Western blot analysis
Cells were washed with ice-cold PBS and then cell lysates were prepared as previously described (17) . Lysate proteins were boiled for 5 min in Laemmli sample buffer, size-fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and then electroblotted onto polyvinylidene difluoride membranes. The blots were incubated with primary antibodies and visualized using a chemiluminescence kit (Amersham Biosciences, Piscataway, NJ, USA).
Statistical analyses
Data are expressed as the mean ± S.E.M. from at least three independent experiments. Statistical analysis was performed by the Student's t-test. ANOVA was performed for serial analysis.
Results
Effect of pravastatin on rAEC proliferation
EC proliferation is a crucial process for angiogenesis. Recently, cerivastatin and pitavastatin were reported to stimulate EC proliferation (8, 10) . First, we investigated whether pravastatin is also capable of promoting rAEC proliferation. rAECs were incubated with different concentrations of pravastatin for three days and proliferation was assessed (Fig. 1) . As reported with different statins (8, 10) , low concentration (1 µM) of pravastatin increased rAEC proliferation by 20%, whereas high concentration (100 µM) did not have this effect. Pravastatin-induced proliferation of rAEC was reversed by the product of the HMG-CoA reductase, mevalonate.
Pravastatin induces phosphorylation of Akt, FoxO1, FoxO3a, and p70S6K in rAECs
In ECs, the majority of growth factor-induced responses are mediated by the activation of PI3K / Akt signaling (14) . We analyzed whether pravastatin activates this pathway in rAECs; cells were stimulated with 1 µM of pravastatin for 0 -60 min and cell lysates were prepared and subjected to Western blot analysis. As shown in Fig. 2A , the addition of pravastatin to rAECs resulted in rapid phosphorylation of Akt at Ser . We next tested the effect of pravastatin on the phosphorylation of a PI3K / Akt downstream target, p70S6K. p70S6K plays a role in regulating the translation machinery and is controlled by mTOR, an immediate downstream effecter of Akt (18) . As shown in Fig. 2B , pravastatin induced the phosphorylation of p70S6K on Thr 389 and Thr 421 / Ser
424
, thereby leading to enzyme activation. Pretreatment of cells with LY294002, a specific PI3K inhibitor, abolished the phosphorylation of Akt and p70S6K, whereas pretreatment with rapamycin, a specific inhibitor of mTOR, inhibited only p70S6K activation (Fig. 3: A and B) . These results demonstrated that pravastatin activates PI3K / Akt / mTOR/ p70S6K signaling in this sequential manner in rAEC. Because forkhead transcription factors are also Fig. 1 . Effect of pravastatin on rAEC proliferation. rAECs (3 × 10 4 ) were seeded onto a 6-well plate and cultured in serum-reduced media for 18 h. The cells were then stimulated with increasing concentration of pravastatin for an additional 72 h. Viable cell numbers were monitored by trypan blue dye exclusion. Each column represents the mean ± S.E.M. of six different experiments. Data were compared by ANOVA. *P<0.05, compared to pravastatin minus the control. Fig. 2 . Pravastatin induces phosphorylation of Akt, p70S6K, FoxO1, and FoxO3a. rAECs were incubated in serum-reduced medium for 18 h and then stimulated with pravastatin (1 µM) for the indicated time periods. Whole cell lysates were prepared; and the phosphorylation of Akt (A), p70S6K (B), or FoxO1/FoxO3a (C) was analyzed by Western blotting. As a loading control, the membranes were stripped and reprobed with antibodies for the total level of each protein.
downstream targets of Akt and are inactivated by Aktdependent phosphorylation of serine / threonine residues (19), we investigated whether pravastatin may phosphorylate and, thereby, inactivate the forkhead transcription factors. As shown in Fig. 2C , pravastatin also phosphorylated FoxO1 and FoxO3a with the same kinetics as for Akt and p70S6K.
Pravastatin-induced rAEC proliferation requires activation of PI3K /Akt /mTOR /p70S6K signaling To find the role of PI3K / Akt / mTOR/ p70S6K signaling in rAECs, we next tested the effect of LY294002 and rapamycin on pravastatin-induced proliferation in these cells. rAECs were incubated with or without 1 µM of pravastatin in the presence or absence of LY294002 (50 µM) or rapamycin (2.5 nM) for 3 days, and then the cell numbers were counted. As shown in Fig. 4 , LY294002 markedly suppressed both basal and pravastatin-induced rAEC proliferation. Because PI3K has many downstream targets that are essential for cell survival (11), it is quite possible that inhibition of PI3K may trigger cell death and thereby account for the observed decrease in the cell number. Inhibition of mTOR by rapamycin also suppressed basal rAEC proliferation, but the suppression level was much smaller than that induced by LY294002. Indeed, both LY294002 and rapamycin inhibited pravastatin-induced rAEC proliferation. These results indicate that pravastatin-induced proliferation in rAEC is mediated through both PI3Kand mTOR signaling.
Pravastatin-induced rAEC migration requires activation of PI3K /Akt /mTOR /p70S6K signaling Because EC migration is also known to be an important event in angiogenesis, we further investigated the role of PI3K / Akt / mTOR/ p70S6K signaling in pravastatin-induced migration of rAECs. Migration assays were performed by two independent approaches: a scratch wound assay and a Boyden chamber assay. Consistent with their effects on proliferation, LY294002 and rapamycin also clearly suppressed both basal and pravastatin-induced rAEC migration in the scratch wound assay (Fig. 5A) . Similar results were found in the Boyden chamber assay. Pravastatin increased the number of migrated cells into the lower chamber, and the effect of pravastatin was significantly suppressed by both inhibitors (Fig. 5B) . These results indicate that the PI3K / Akt / mTOR / p70S6K pathway contributes to Fig. 3 . Pravastatin induces phosphorylation of Akt and p70S6K in a PI3K-dependent manner. Quiescent rAECs were preincubated with the indicated concentrations of LY294002 or rapamycin for 30 min, and then the cells were stimulated with pravastatin (1 µM) for 10 min. Whole cell lysates were prepared and the phosphorylation of Akt (A) or p70S6K (B) was analyzed by Western blotting. As a loading control, the membranes were reprobed with antibodies for the total level of each protein. Fig. 4 . Effect of LY294002 or rapamycin on pravastatin-induced rAEC proliferation. rAECs were seeded onto a 6-well plate and incubated in serum-reduced media for 18 h. Cells were then treated with vehicle or pravastatin (1 µM) in the presence or absence of LY294002 (50 µM) or rapamycin (2.5 nM) for an additional 72 h. Viable cell numbers were monitored by trypan blue dye exclusion. Each column represents the mean ± S.E.M. of three different experiments, *P<0.05. n.s. = not significant rAEC migration as well as cell proliferation.
Pravastatin-induced Akt/p70S6K phosphorylation is not concentration-dependent
We demonstrated that low concentration (1 µM) of pravastatin enhanced rAEC proliferation, whereas higher concentration of pravastatin (>10 µM) did not have the effect (Fig. 1) . Finally, we examined the effect of highconcentration pravastatin on Akt / p70S6K phosphorylation in rAECs. rAECs were stimulated with 1, 10, or 100 µM of pravastatin for 10 min, and then cell lysates were prepared and subjected to Western blot analysis. As shown in Fig. 6 , pravastatin had no concentrationdependent effect on the phosphorylation of Akt, p70S6K, and FOXO1 / FOXO3a.
Discussion
This is the first study to demonstrate that pravastatin induces the activation of the mTOR / p70S6K pathway and that this pathway mediates pravastatin-induced rAEC proliferation and migration. It is well established that the PI3K / Akt pathway is implicated in multiple cellular and organ functions, including growth, cell survival, cell proliferation, and glucose metabolism (18, 20 -22) . In ECs, the PI3K / Akt pathway has been shown to play an important role in mediating cell survival, proliferation, and migration (14, 23) . The serine / threonine kinase mTOR is an important downstream target of PI3K/ Akt, and mTOR signaling has been shown to be involved in the control of cell growth and proliferation Effect of LY294002 or rapamycin on pravastatin-induced rAEC migration. A: rAECs were incubated with 1 µM of pravastatin in the absence or presence of the indicated inhibitors for 48 h, and cell migration was detected by using a scratch wound assay. The central dark line indicates the boundary between the unscratched and scratched areas. B: Cell migration was measured by using a Boyden chamber assay. rAECs were preincubated either with or without pravastatin (1 µM) for 24 h, and then 50 µl of cell suspension at 1 × 10 6 cells /ml was added to the upper well of the chamber in the absence or presence of the respective inhibitor. The cells that migrated and adhered to the lower surface of the membrane were counted. Each column represents the mean ± S.E.M. of three different experiments, *P<0.05 vs pravastatin-treated cells in the absence of inhibitors. Fig. 6 . Concentration-response of Akt, p70S6K, FOXO1, and FOXO3a phosphorylation in pravastatin-stimulated rAECs. rAECs were stimulated with various concentrations of pravastatin for 10 min and then whole cell lysates were prepared and the phosphorylation of each protein was analyzed by Western blotting. As loading controls, the membranes were reprobed with an α-tubulin antibody. (24) . Recent publications have demonstrated that mTOR is found in two separate complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (25 -30) . mTORC1 contains mTOR in association with GβL and raptor proteins. mTORC1 activation leads to phosphorylation of p70S6K, and mTORC1 signaling is inhibited by rapamycin. mTORC2 also contains mTOR and GβL, but instead of raptor, it contains two other proteins, rictor and mSin1. In contrast to mTORC1, mTORC2 signaling is not rapamycin-sensitive. It has been shown that mTORC1, but not mTORC2, is the downstream target of the Akt and that the PI3K / Akt/ mTOR / p70S6K pathway plays an important role in the control of cell growth and proliferation (24, 31) . The role of the mTOR pathway in ECs has not been fully understood. Recently, Zhang et al. demonstrated that 15(S)-hydroxyeicosatetraenoic acid activates the PI3K / Akt/ mTOR / p70S6K pathway and activation of this pathway induces tube formation and migration of human dermal microvascular ECs in vitro and Matrigel plug angiogenesis in vivo (32) . In addition, Li and coworkers showed that hypoxia-induced rAEC proliferation requires mTORC1 signaling (33) . These observations indicate that the mTOR signaling pathway plays an important role in angiogenesis. In the present study, we found that pravastatin also activates the mTOR / p70S6K pathway in ECs, and this activation is completely inhibited by both LY294002 and rapamycin. These results raise the possibility that pravastatin enhances angiogenesis via the PI3K / Akt/ mTORp70S6K signaling pathway.
Angiogenesis is a major physiological response to ischemia that involves a sequence of events resulting in development of new capillaries from preexisting vessels (7) . This complex multistep process includes cell proliferation, migration, and differentiation of ECs; and it is regulated by many proangiogenic growth factors, including VEGF, bFGF, and angiopoietin-1 (12, 13, 34) . Other than these growth factors, recent studies have revealed that statins have angiogenic effects on ECs (8 -10) . At therapeutic doses, statins promote proliferation, migration, and survival of ECs (8, 9) . Moreover, statins induce mobilization and differentiation of bone marrow-derived endothelial progenitor cells (EPCs) (35, 36) . Weis and coworkers reported that cerivastatin has a biphasic effect on mature EC proliferation. They have shown that cerivastatin significantly enhanced EC proliferation at low concentrations, but inhibited the event at higher concentrations (8) . In addition, Katsumoto et al. recently demonstrated that pitavastatin also exerts a biphasic effect on EC proliferation (10) . In the present study, we demonstrated that low concentrations of pravastatin enhanced rAEC proliferation, whereas higher concentrations of the statin did not. We also showed that this proliferative effect of pravastatin is closely related to the PI3K / Akt activity. In our experimental conditions, 50 µM of LY294002, a highly selective PI3K inhibitor, almost completely inhibited pravastatin-induced Akt phosphorylation in rAEC and markedly suppressed both basal and pravastatin-induced rAEC proliferation and migration. Because PI3K has many downstream targets that are essential for cell survival, it is quite possible that inhibition of PI3K may cause cell death and thereby account for the observed decrease in the cell proliferation and migration. On the other hand, rapamycin also inhibited both basal and pravastatin-induced proliferation, although the amount of suppression was smaller than that induced by PI3K inhibition. These results suggest that the effect of PI3K activation of cell survival in ECs may be mediated in part by the mTOR pathway.
In our study, the Akt/ p70S6K pathway was robustly activated by pravastatin, whereas the proliferation effect of the drug was not very potent. Pravastatin at 1 µM increased cell proliferation by only 20% compared to the control. Weis et al. also demonstrated that the effect of cerivastatin is modest; low concentrations of cerivastatin increased cell proliferation by only 10% -20% in human adult dermal microvascular ECs (HMVECs) and HMEC-1, an immortalized human dermal microvascular EC line (8) . In addition, Katsumoto et al. demonstrated that a low concentration of pitavastatin enhanced FGF-2-induced proliferation of human epidermal microvessel ECs by 29% compared to pitavastatin minus the control (10) . Taken together with our results, it is concluded that the effect of statin on EC proliferation is only modest. On the other hand, it was reported that phosphorylation of Akt targets is likely to contribute to other EC functions including survival, growth, and migration (14) . It may be possible that the effect of the statin on EC proliferation is not potent because this signaling pathway might be involved not only in EC proliferation but also in other EC functions such as EC survival, growth, and migration. Further studies are needed to address this issue.
In the present study, we found that high concentrations of pravastatin (>10 µM) clearly induced Akt / p70S6K phosphorylation, whereas these concentrations of the statin failed to enhance rAEC proliferation (Fig. 6 ). Weis and coworkers indicated that at high concentrations, a statin-induced reduction in geranylgeranyl pyrophosphate (GGP) inhibits EC proliferation and migration. They speculate that high-concentration statins induce EC apoptosis in part by reducing geranylgeranylation of Rho proteins known to modulate the activity of vascular endothelial growth factor receptor-2 (VEGFR-2) (8). It may be possible that high-concentration pravastatin inhibits EC proliferation in part by other molecules that are not related with PI3K / Akt/ mTOR / p70S6K signaling.
In addition to mTOR / p70S6K, we found that pravastatin induces the phosphorylation of FoxO1 and FoxO3a, members of the FoxO (Forkhead box, class O) subfamily of forkhead transcription factors. FoxO transcription factors have been identified as direct targets of the PI3K / Akt pathway (37) . In response to mitogenic stimuli, Akt can phosphorylate the members of this family, preventing their translocation to the nucleus where they would otherwise function to promote the transcription of cell cycle inhibitors such as p27Kip1 and proapoptotic molecules such as Fas ligand (37 -39) . Abid et al. demonstrated that VEGF promotes mature EC survival, proliferation, and cell-cycle progression via a PI3K/ forkhead pathway (40) . In addition, Urbich et al. demonstrated that atorvastatin induces the phosphorylation of FoxO4, another member of the FoxO forkhead transcription factors, in EPCs and reduces oxidative stress-induced EPC apoptosis via PI3K / Akt/ FoxO4 signaling (41) . These results suggest that the statininduced inactivation of forkhead transcription factors may play a significant role in mature ECs.
In summary, the present observations show that pravastatin has a biphasic effect on rAEC proliferation. In addition, low concentrations of pravastatin can induce proliferation and migration via PI3K / Akt/ mTOR / p70S6K signaling in rAECs. Our findings suggest the possibility that the mTOR / p70S6K pathway may play an important role in some of the pleiotropic effects of statins.
